especially in bio-pharmaceutical area as a whole. ����Don't just focus on the technical level

Bio-generic drugs have the opportunity to become medical focus of most attention in recent years. A set of data is the most eye-catching: 2010 global sales reached US $ 850 billion in drug market swtor power leveling, where biotechnology drugs and generic drugs and record, reached US $ 140 billion and $ 120 billion, respectively. In the United States outside of bio-generic drugs salesAbove $ 1 billion. November 25, organised by the biological effects of bio-generics Summit Forum held in Shanghai, Forum around the "bio-imitation pharmaceutical industry trends and key technologies" and other topics for in-depth discussion and analysis of comprehensive interpretation. Experts believe that in 2013, 2014, a group of bio-pharmaceutical patents expire will focus. United States FDAFor bio-generic drug legislation has to be out of the oven, bodes well for bio-generics in the next 5-10 will usher in a significant development opportunity. Experts said China has licensed 13 25 382 different specifications of the products of genetic engineering medicine and genetic engineering vaccine, only 6 9 21 specifications of products belonging to the original, the rest belongs to the clone.In the listed company, hisun pharmaceutical industry (600,267) in hand, Pfizer, the first sign of joint moshadong of the drugs industry, fosun pharmaceutical (600,196) and Longshan Group marriage, were seen as representatives of domestic business of bio-generics. It is learnt that the bio-generic drug research and development in our country has a certain basis. A case study of Shanghai, Shanghai Institute of biological products already have, huaxin bio, Wanxing bio and other 7 companies have drugs such as interferon, human growth hormone. ����According to the Shanghai Municipal Deputy Director Fu Daxu bio-medicine industry promotion center of science and technology introduction, "Twelve-Five" period of recombinant cytokine drugs and biological treatment of industrial development, will focus on the innovation of new target cytokine gene therapy, somatic cell therapy and genetic engineering research. SectionLi Xiangming researcher of the Department's technical adviser on biological imitation pharmaceutical enterprises in China to make recommendations, before the patent expires, just ahead of layout of imitation, and would increase the indications, and so on, are all bio-generics opportunity. ����But whether companies had the opportunity, also is to see whether there are patents, core technology. Strategic partnership and the bio-pharmaceutical company limited, Director Chen Rulei told reporters, according to an authoritative forecasterData of the cloth by 2021 the global bio-generic drug to reach 250 billion dollars. He also said that technically successful, ranging from commercial success star wars the old republic power leveling, especially in bio-pharmaceutical area as a whole. ����Don't just focus on the technical level, market sales and channels is also vital, to have a marketing effort, businesses will only succeed. Chinese medicine (60,0056) science and technology achievements transformation Rui Guozhong, Director of the Centre reminds, the domestic drug innovation, must consider good business ideas, and innovations in the market, is not available for innovation, innovation, innovation for the business. CIC securities believes that specifications such as bio-generic drug market is growing rapidly in Europe and America, recombinant proteins and monoclonal antibody drugs to the bio-generics industry a huge space for development.